Update: Influenza Activity in the United States During the 2017–18 Season and Composition of the 2018–19 Influenza Vaccine

The United States 2017–18 influenza season (October 1, 2017–May 19, 2018) was a high severity season with high levels of outpatient clinic and emergency department visits for influenza-like illness (ILI), high influenza-related hospitalization rates, and elevated and geographically widespread influenza activity across the country for an extended period. Nationally, ILI activity began increasing in November, reaching an extended period of high activity during January–February, and remaining elevated through March. Influenza A(H3N2) viruses predominated through February and were predominant overall for the season; influenza B viruses predominated from March onward. This report summarizes U.S. influenza activity* during October 1, 2017–May 19, 2018.

Virus Surveillance

CDC receives influenza test results from public health and clinical laboratories located in all 50 states, Puerto Rico, and the District of Columbia through U.S. World Health Organization (WHO) Collaborating Laboratories and the National Respiratory and Enteric Virus Surveillance System (NREVSS). During October 1, 2017–May 19, 2018, clinical laboratories tested 1,210,053 specimens for influenza virus; 224,113 (18.5%) tested positive (Supplementary Figure 1, https://stacks.cdc.gov/view/cdc/54973), including 151,413 (67.6%) for influenza A and 72,700 (32.4%) for influenza B. Nationally, the percentage of clinical laboratory–tested specimens positive for influenza virus peaked for 5 consecutive weeks during January 13–February 10 (surveillance weeks 2–6) (range = 26.1%–26.9%). Regionally,§ the week of peak clinical laboratory influenza positivity varied, ranging from the week ending December 30 (week 52) to the week ending February 17 (week 7).

Public health laboratories tested 98,446 specimens during October 1, 2017–May 19, 2018; 53,790 (54.6%) were positive for influenza viruses, including 38,303 (71.2%) positive for influenza A and 15,487 (28.8%) for influenza B (Supplementary Figure 2, https://stacks.cdc.gov/view/cdc/54974). Among the 37,681 seasonal influenza A viruses subtyped, 31,977 (84.9%) were influenza A(H3N2), and 5,704 (15.1%) were influenza A(H1N1)pdm09. Influenza B lineage information was available for 11,950 (77.2%) influenza B viruses; 10,612 (88.8%) were B/Yamagata lineage, and 1,338 (11.2%) were B/Victoria lineage. Whereas influenza A(H3N2) viruses accounted for the majority of circulating viruses, the proportion of influenza A viruses subtyped as A(H1N1)pdm09 ranged regionally from 9.0% in the central United States to approximately 24% in the northwestern and southeastern United States. Influenza B viruses were more commonly reported than were influenza A viruses from early March to late May (weeks 9–20). The proportion of influenza B viruses reported regionally ranged from 23.0% in the Midwest to 40.6% in the northwestern United States.

Among 47,121 (87.6%) patients who tested positive for seasonal influenza virus by public health laboratories and for whom age data were available, 3,802 (8.1%) were aged 0–4 years; 11,550 (24.5%), 5–24 years; 15,597 (33.1%), 25–64 years; and 16,172 (34.3%), ≥65 years. Influenza A(H3N2) viruses predominated among all age groups, ranging from 51.2% of viruses among persons aged 5–24 years to 70.0% among persons aged ≥65 years. The largest proportion of reported influenza B viruses (36.5%) occurred in persons aged 5–24 years.

Read more…

 

By |2018-06-09T13:30:46+00:00June 9th, 2018|

Leave A Comment

css.php